Biogen/ US09062X1037 /
2024-03-28 8:59:58 PM | Chg. -0.68 | Volume | Bid- | Ask- | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
215.49USD | -0.31% | 72,254 Turnover: 15.57 mill. |
-Bid Size: - | -Ask Size: - | 31.34 bill.USD | - | 26.89 |
GlobeNewswire
03-13
Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer
GlobeNewswire
03-11
Hyku Biosciences, a Covalent Precision Medicine Company, Announces CEO Transition for its Next Phase...
GlobeNewswire
03-08
From the Beach to the Boardroom: Unispace's 'Art for Impact' Program Partners with NGO to Turn 50,00...
GlobeNewswire
03-07
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Biogen Inc. - BI...
GlobeNewswire
03-06
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) i...
GlobeNewswire
03-04
Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (...
GlobeNewswire
02-28
Promising Pathways to Simplified Alzheimer's Diagnosis Unveiled in Groundbreaking Study
GlobeNewswire
02-27
Denali Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlig...
GlobeNewswire
02-24
BIOGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Biogen Inc. on Behalf of Biogen Stockhold...
GlobeNewswire
02-23
Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positiv...
GlobeNewswire
02-22
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen’s Leqembi, A...
GlobeNewswire
02-22
C4 Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business High...
GlobeNewswire
02-20
Mestag Therapeutics Enlists Leading Cancer Biology and Immunology Advisors to Support Clinical Devel...
GlobeNewswire
02-12
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Tr...